Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm, Residual 1

Interventions

Magnetic Resonance Spectroscopy 287Specimen Handling 285pembrolizumab 258Cyclophosphamide 237Radiotherapy 233Nivolumab 187Cisplatin 174Biopsy 170Carboplatin 155Radiosurgery 142fludarabine 131Blood Specimen Collection 130Surveys and Questionnaires 120Gemcitabine 120Paclitaxel 115venetoclax 114Standard of Care 112Dexamethasone 105Bevacizumab 98Radiation 97Rituximab 92Oxaliplatin 89Cytarabine 88Capecitabine 88Drug Therapy 86Ipilimumab 85Doxorubicin 83durvalumab 81atezolizumab 76fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × tetrathiomolybdate × 90 days × Clear all
NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Dartmouth-Hitchcock Medical Center

Phase 1/2 Recruiting
204 enrolled
Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡